Treatment of schizophrenia with venlafaxine

Phase 3

• Conditions: Schizophrenia.; Schizophrenia

• Registration Number: IRCT2012101011076N1
• Lead Sponsor: Kurdistan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Inclusion criteria
(1)-DSM-IV diagnosis for shizophrenia.
(2)-Age between 18-59 years old.
(3)-Not presenting of moderate to severe depression according to the beck depression inventory.
(4)-Total PANSS Sc ore>60.
(5)- Present of significant negative symptoms (PANSS negative sub score>20).
(6)-Patient medication dose does not change during past 3 month of study.
(7)-Patient's medications must be risperidone or olanzapin.
(8)-Obtaining the written informed consent.
Exclusion criteria:
(1)-Additional diagnosis in axis 1 according to DSM-IV.
(2)-Substance abuse or dependence except nicotine.
(3)-Pregnant women.
(4)-Women in fertility ages which does not use OCP.
(5)-History of allergic reaction to venlafaxine.
(6)-Giving ECT during previous 2 months.
(7)- On methadone maintenance therapy.
(8)-Patients with increased intra ocular pressure or in the risk of close angle glaucoma.
(9)-Hepatic cirrhosis.
(10)-Breast feeding women.
(11)-Cimetidine consumption in the presence of HTN or hepatic impairment.
(12)-Another psychotropic drugs consumption except benzodiazepins.
(13)-Mental Retardation.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of schizophrenia. Timepoint: Before study as baseline;4 weeks after beginning of study;6 weeks after beginning of study and 8 weeks after beginning of study. Method of measurement: PANSS inventory.

Secondary Outcome Measures

Name	Time	Method
Side effects. Timepoint: Before study as a baseline;4 weeks after beginning of study;6 weeks after beginning of study and 8 weeks after beginning of study. Method of measurement: ESRS inventory.;Severity of psychiatric symptoms. Timepoint: Before study as baseline;4 weeks after beginning of study;6 weeks after beginning of study and 8 weeks after beginning of study. Method of measurement: BPRS inventory.